Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion – Genitourinary tumours, non-prostate

4138 - ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma.


29 Sep 2019


Poster Discussion – Genitourinary tumours, non-prostate


Lewis Au


Annals of Oncology (2019) 30 (suppl_5): v356-v402. 10.1093/annonc/mdz249


L. Au1, K. Litchfield1, A. Rowan1, S. Horswell1, F. Byrne1, D. Nicol2, N. Fotiadis3, R.F. Salgado4, S. Hazell5, J.I. Lopez6, E. Hatipoglu7, L. Del Rosario8, L. Pickering8, M. Gore8, B. Chain9, S. Quezada10, J.M.G. Larkin11, C. Swanton1, S. Turajlic12

Author affiliations

  • 1 Cancer Evolution And Genome Instability Laboratory, The Francis Crick Institute, NW1 1ST - London/GB
  • 2 Department Of Surgery, Royal Marsden Hospital NHS Foundation Trust, SW6 1EJ - London/GB
  • 3 Interventional Radiology Unit, Royal Marsden NHS Foundation Trust, SM2 5PT - Sutton/GB
  • 4 Department Of Pathology, St-Augustinus Ziekenhuis, 2580 - Wilrijk/BE
  • 5 Department Of Pathology, Royal Marsden Hospital NHS Foundation Trust, SW6 1EJ - London/GB
  • 6 Department Of Pathology, Cruces University Hospital, Bilbao/ES
  • 7 Cancer Immunology Unit, University College London Cancer Institute, London/GB
  • 8 Skin And Renal Unit, Royal Marsden Hospital NHS Foundation Trust, SW6 1EJ - London/GB
  • 9 Division Of Infection And Immunity, Imperial College London, EJ - London/GB
  • 10 Cancer Institute, University College London, WC1E 6DD - London/GB
  • 11 Medicine, Royal Marsden Hospital NHS Foundation Trust, SW6 1EJ - London/GB
  • 12 Cancer Evolution And Genome Instability Laboratory, The Francis Crick Institute, NW1 1AT - London/GB


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4138


ADATPeR is the first prospective study evaluating the role of anti-PD1 agents in the neoadjuvant setting prior to cytoreductive nephrectomy in treatment-naïve patients with metastatic clear cell renal cell carcinoma (mccRCC). We performed multi-omic analyses to resolve spatial heterogeneity and temporal dynamics in putative biomarkers of response to anti-PD1 blockade.


In a single center study, patients received nivolumab (3mg/kg every 2 weeks) pre- and post-operatively until progressive disease (PD). Primary endpoint was safety, secondary endpoints were response evaluation and exploratory biomarker analysis. Multiregion tumour biopsies were obtained at baseline, on-treatment (week 9) and at PD. Whole-exome sequencing was performed to infer somatic mutations and predict candidate neoantigens (NAs). Tumour immune microenvironment was evaluated using a RNA-seq-derived immune signature and by stromal and intraepithelial tumour infiltrating lymphocytes (TILs) assessments.


15 patients were treated. At median follow-up of 12.5 months(m), nivolumab had an acceptable side-effect profile. Overall response rate was 37%. Preliminary transcriptome analyses of pre-treatment biopsies (33 samples from 14 patients; up to 4 regions per case) revealed enrichment for primary-resistance (defined as PD within 2m; n = 4) with immune ‘cold’ tumours, distinct from ’hot’ tumours. Histologic TILs scoring showed concordant immune phenotypic clusters. Primary-resistant cases demonstrated 0% on-treatment stromal- and IE-TILs (2 evaluable patients). In contrast, we observed heavy on-treatment stromal TILs (70-90%) and intraepithelial TILs (30-90%) across 7 regions at nephrectomy in an exceptional responder receiving ongoing treatment (>24 cycles).


ADATPeR is the first neoadjuvant immune checkpoint inhibitor study pre-cytoreductive nephrectomy, and incorporated multi-omic analyses of putative biomarkers. Baseline immune gene expression signature is distinct in responders compared with non-responders. On-treatment intraepithelial TILs were prominent in those deriving durable clinical benefit. Integrative analyses are ongoing.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

The authors.


Bristol-Myers Squibb; The National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research; Cancer Research UK (CRUK).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.